GE
21.4.2021 09:02:13 CEST | Business Wire | Press release
GE Renewable Energy’s Grid Solutions business (NYSE: GE) and Hitachi ABB Power Grids Ltd. announced today a non-exclusive, cross-licensing agreement related to the use of an alternative gas to sulfur hexafluoride (SF6 ) used in high voltage equipment. This fluoronitrile-based gas mixture has a significantly reduced impact on the environment compared to SF6 .
Under this landmark agreement announced just before Earth Day 2021 between two global leaders in power technologies – both companies will share complementary intellectual property related to their respective SF6 -free solutions. This will help accelerate the use of fluoronitrile-based eco-efficient insulation and switching gas in high-voltage equipment as an alternative to SF6 . A recent EU Commission report concluded that fluorinitrile-based gas mixtures may be the only insulating and switching gas alternative to SF6 when space is a constraint.
Today’s historic agreement paves the way for a standard SF6 -free solution for high-voltage equipment in the coming years. This would enable utilities and industries to accelerate their reduction of greenhouse gas emissions, while facilitating their ability to plan, as well as operate and maintain their networks thanks to standardized services and the use of the same auxiliary equipment.
For almost half a century, SF6 gas has been the norm in the electrical power transmission and distribution industry due to its unique physical properties. It is, however a greenhouse gas that contributes to global warming if leaked. For this reason, GE and Hitachi ABB Power Grids have been investing in the development of better alternatives to SF6.
“Utilities are becoming increasingly aware of their environmental footprint and the impact it has on their communities and the world around them. Today’s landmark agreement reinforces our commitment to help our customers to reduce their greenhouse gas emissions,” said Heiner Markhoff, CEO of GE’s Grid Solutions. “GE pioneered this fluoronitrile-based gas which we named g3 and subsequently developed a broad SF6 -free product range. Our g3 SF6 -free products have been commercially available since 2015 and feature the same compactness and performance as traditional SF6 equipment,” he added.
“As part of our commitment towards a carbon-neutral future and accelerating the energy transition, we have chosen to work towards a standard solution to address the needs of our customers through this cross-licensing agreement,” said Markus Heimbach, Managing Director of the High Voltage Products business in Hitachi ABB Power Grids. “As a technology leader, we have always been at the frontier of gas-insulated switchgear (GIS) that became a key enabler for urbanization and installed the very first SF6 -free GIS that significantly reduces carbon footprint,” he added.
The two companies will keep the product development, manufacturing, sales, marketing and service activities of their gas solutions fully independent. Each company will continue to independently grant and set terms of licenses to its respective intellectual property, hence preserving supplier base diversity for the industry and fair competition.
Notes to Editor:
GE’s alternative to SF6 is g3 insulating and switching gas. The global warming potential (GWP) of GE’s g3 gas is more than 99% lower compared to SF6 . More: g3 - SF6-free solutions .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005141/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Spin-Off Clee Medical Secures Seed Financing to Bring Real-Time Vision to Brain Surgery26.2.2026 12:49:00 CET | Press release
The Wyss Center for Bio and Neuroengineering Geneva announced today the successful closing of the Seed financing round of Clee Medical SA, a Swiss neurotechnology spin-off developing ultra-high-resolution real-time intraoperative imaging for brain surgery. The round was led by High-Tech Gründerfonds (HTGF), with participation from Zürcher Kantonalbank (ZKB), Kickfund, FONGIT, and Venture Kick joining existing investors Wyss Center Geneva. Clee Medical spun-out from Wyss Geneva’s Minimally Invasive Intracranial Access (MICA) research project in December 2024. Its flagship platform, Neuro Access, combines OCT imaging with advanced navigation to help neurosurgeons visualize brain anatomy and critical structures in real time during stereotactic procedures. “Clee Medical not only holds the promise of improving patient outcomes but also highlights Wyss Geneva’s dedication to bridging the gap between scientific discovery and real-world impact.” Dr. Erwin Böttinger, CEO, Wyss Geneva “Neurosurg
Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants26.2.2026 12:30:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the exercise of 35,059,448 warrants, which were issued on January 13, 2025, for proceeds of approximately $200 million. Upon exercise of these outstanding warrants, Compass Pathways is issuing 15,160,619 American Depositary Shares (“ADSs”) and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 19,898,829 ADSs. Compass Pathways currently intends to use the proceeds from these warrant exercises, together with its existing cash and cash equivalents, to fund ongoing COMP005 and COMP006 Phase 3 trials, its Phase 2b/3 trial of COMP360 in PTSD, acceleration of its commercial readiness activities, and for working capital and general corporate purposes. The net proceeds from these warrant exercises, along with the net proceeds of approximately $141 million from the recent public offering that closed on Februar
BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership26.2.2026 12:00:00 CET | Press release
Total global revenues of $1.5 billion and $5.3 billion for the fourth quarter and full year, increases of 33% and 40% from the prior-year periodsGlobal BRUKINSA (zanubrutinib) revenues of $1.1 billion and $3.9 billion for the fourth quarter and full year, increases of 38% and 49% from the prior-year periodsDiluted GAAP Earnings per American Depository Share (ADS) of $0.58 and $2.53 for the fourth quarter and full year; non-GAAP diluted Earnings per ADS of $1.95 and $8.09 for the fourth quarter and full yearFull year 2026 total revenue guidance of $6.2 billion to $6.4 billion BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the fourth quarter and full year 2025. “These strong financial results for the fourth quarter and full year 2025 underscore our continued evolution as a global oncology leader with durable competitive advantages in clinical development and manufacturing and one of the
ThreatAware Secures $25M from One Peak to Give Security Teams the Power to Build26.2.2026 11:00:00 CET | Press release
Bootstrapped to profitability and 100+ clients, ThreatAware launches its AI-powered security workspace that gives security teams the freedom to build exactly what they need. ThreatAware, the cyber asset management and cyber hygiene platform trusted by enterprises across sectors including retail, financial services, and energy, today announced it has raised $25 million in funding from One Peak, the growth equity firm specialising in high-growth software scale-ups. The investment will help ThreatAware scale its rapidly growing North American operations and accelerate its ambitious product roadmap, including the launch of ThreatAware's AI-powered security workspace. At the heart of ThreatAware's platform is its proprietary cyber asset management technology, which solves a problem most organisations don't even know they have. ThreatAware's data consistently reveals that, on average, 10% of devices accessing corporate networks go completely undetected by existing tools, while 30% of securit
Cyviz Unveils Containerized C2 Solution During HEIMDALL26.2.2026 11:00:00 CET | Press release
During Exercise HEIMDALL, organized by the Norwegian Joint Headquarters (FOH/NJHQ) this week, Cyviz is presenting its fully integrated, containerized solution for command, control, and collaboration environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226587573/en/ From deployment to operations: Cyviz’ container‑based C2 solution demonstrated during Exercise HEIMDALL. James Munt, Sales Director from Cyviz, took part in the demonstration. The solution is designed for secure, standardized, and agile operations, enabling operators to fight at the edge with assured information and supporting faster decision-making, in line with the company’s strategic focus on the defense and security sector. The container solution has been developed in collaboration with Nordic Shelter, providing the container platform. The modular platform combines control room technology, visualization, and software into one integrated system. It’s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
